Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

January 2023

Effets indésirables de la grippe chez les patients atteints de polyarthrite rhumatoïde, de rectocolite hémorragique ou de rhumatisme psoriasique dans le cadre des programmes de développement clinique du tofacitinib

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00507-z

Jo H,

Kwok K,

Shapiro AB,

Jones TV,

Diehl A,

Su C,

Panés J,

Cohen SB

This post-hoc analysis of 31 clinical trials in ulcerative colitis, rheumatoid arthritis and psoriatic arthritis concludes that combined influenza adverse event incidence rates were highest in ulcerative colitis, while in each indication they were generally similar across tofacitinib, placebo, and comparator groups.

Keywords:

September 2022

Infections chez les patients atteints de polyarthrite rhumatoïde recevant du tofacitinib versus des inhibiteurs du facteur de nécrose tumorale : résultats de l'essai de Surveillance ORAL ouvert, randomisé et contrôlé

doi: 10.1136/ard-2022-222405

Gold D,

Chen AS,

Sawyerr G,

Shapiro AB,

Pope JE,

Schulze-Koops H

Post hoc analysis, using the final dataset from ORAL Surveillance, reveals a higher risk of non-serious infections and herpes zoster with tofacitinib vs TNFi, and higher risk of serious infection events with tofacitinib 10 mg BID versus TNFi, particularly in patients aged ≥65 years.

Keywords:

February 2022

Cardiovascular and Cancer Risk With Tofacitinib in Rheumatoid Arthritis

N Engl J Med 2022;386:316–26. doi: 10.1056/NEJMc2202778

Koch GG,

Menon S,

Sun Y,

Wang C,

Shapiro AB,

Kanik KS,

Connell CA

In this paper, Ytterberg et al. compare incidence of MACE and cancers (excluding NMSC) with tofacitinib 5 mg BID, tofacitinib 10 mg BID and TNFi. They found that risk of MACE and cancer were higher with tofacitinib versus TNFi, and did not meet noninferiority criteria.This prospective head-to-head safety trial compared tofacitinib to TNFi, and was required by the FDA after increases in lipid levels and cancers were observed during tofacitinib drug development. ...

Keywords:

March 2021

Étude Comparative d'Innocuité Post-Approbation du Tofacitinib et des Antirhumatismaux Biologiques : Résultats à 5 ans à partir d'un Registre de Polyarthrite Rhumatoïde Basé aux États-Unis

ACR Open Rheumatol. 2021 Feb 11.

Geier J,

Barr CJ,

Analysis from the US Corrona RA registry has provided the longest-term real-world safety data for a JAK inhibitor to date. The analysis showed that the cohorts had similar adverse events, except for higher herpes zoster rates for tofacitinib initiators vs bDMARDs.Kremer JM, et al. analysed adult patients with RA newly initiating tofacitinib, or a bDMARD, to compare incidence rates of MACE, SIEs, HZ, malignancies and death. VTE data were also collected prospectively and assessed descriptively thr...

Keywords:

November 2020

Incidence Basée sur l'Âge (<65 ans vs ≥65 ans) des Infections et des Infections Sévères avec le Tofacitinib versus les DMARD Biologiques dans les Essais Cliniques sur la Polyarthrite Rhumatoïde et le Registre Américain Corrona RA

Ann Rheum Dis 2020; DOI: 10.1136/annrheumdis-2020-218992

Gold D,

Shi H,

Reports from clinical trials and the US Corrona RA registry showed that serious infection event (SIE) incidence was higher in older versus younger patients with RA receiving 10 mg BID of TOF and ADA, however, SIE risk was similar between age groups with TOF 5 mg BID and ADA.Data were collected from Phase II–IV tofacitinib studies, and the US Corrona RA registry. The clinical data set evaluated patients receiving TOF 5 and 10 mg BID versus TNFi (ADA/ETN) in RA patients aged ≥50 years. The EMA rec...